Literature DB >> 9102223

Homozygous deletions of human chromosome 3p in lung tumors.

S Todd1, W A Franklin, M Varella-Garcia, T Kennedy, C E Hilliker, L Hahner, M Anderson, J S Wiest, H A Drabkin, R M Gemmill.   

Abstract

Cytogenetic and loss of heterozygosity (LOH) studies have demonstrated that deletions of chromosome 3p occur at a high frequency in all forms of lung cancer. To clarify the role of 3p in lung tumorigenesis and to more precisely identify targets for positional cloning efforts, we have performed 3p deletion analyses (microsatellite and fluorescence in situ hybridization) in a series of lung cancer cell lines and uncultured tumor samples. Importantly, we identified homozygous deletions in four uncultured tumors and one cell line. Homozygous deletions were found in three squamous tumors within a region of 3p21 which had previously been described only in cell lines, a 1-2-megabase homozygous deletion in a small cell tumor at 3p12, and a 3p14.2 homozygous deletion in a non-small cell lung carcinoma cell line. The detection of homozygous deletions affecting these multiple regions in uncultured tumor cells substantiates the belief (previously based on deletions found only in tumor cell lines) that these sites contain important tumor suppressor genes. Along with previously reported homozygous deletions in a distal portion of 3p21.3, we now have evidence for four separate regions of 3p which undergo homozygous deletions in either uncultured lung tumors or cell lines.

Entities:  

Mesh:

Year:  1997        PMID: 9102223

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

Review 1.  Molecular genetic abnormalities in the pathogenesis of human lung cancer.

Authors:  E Forgacs; S Zöchbauer-Müller; E Oláh; J D Minna
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

2.  Computerized polymorphic marker identification: experimental validation and a predicted human polymorphism catalog.

Authors:  J W Fondon; G M Mele; R I Brezinschek; D Cummings; A Pande; J Wren; K M O'Brien; K C Kupfer; M H Wei; M Lerman; J D Minna; H R Garner
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-23       Impact factor: 11.205

3.  Inadequate lung development and bronchial hyperplasia in mice with a targeted deletion in the Dutt1/Robo1 gene.

Authors:  J Xian; K J Clark; R Fordham; R Pannell; T H Rabbitts; P H Rabbitts
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-04       Impact factor: 11.205

4.  Allelic loss in human papillomavirus-positive and -negative vulvar squamous cell carcinomas.

Authors:  A P Pinto; M C Lin; G L Mutter; D Sun; L L Villa; C P Crum
Journal:  Am J Pathol       Date:  1999-04       Impact factor: 4.307

5.  MCG10, a novel p53 target gene that encodes a KH domain RNA-binding protein, is capable of inducing apoptosis and cell cycle arrest in G(2)-M.

Authors:  J Zhu; X Chen
Journal:  Mol Cell Biol       Date:  2000-08       Impact factor: 4.272

6.  Inactivation of the transforming growth factor beta type II receptor in human small cell lung cancer cell lines.

Authors:  S Hougaard; P Nørgaard; N Abrahamsen; H L Moses; M Spang-Thomsen; H Skovgaard Poulsen
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

Review 7.  Preclinical Murine Models for Lung Cancer: Clinical Trial Applications.

Authors:  Amelia Kellar; Cay Egan; Don Morris
Journal:  Biomed Res Int       Date:  2015-05-03       Impact factor: 3.411

8.  Expression of the DMBT1 gene is frequently suppressed in human lung cancer.

Authors:  H Takeshita; M Sato; H O Shiwaku; S Semba; A Sakurada; M Hoshi; Y Hayashi; Y Tagawa; H Ayabe; A Horii
Journal:  Jpn J Cancer Res       Date:  1999-09

9.  The prognostic significance of allelic imbalance at key chromosomal loci in oral cancer.

Authors:  M Partridge; G Emilion; S Pateromichelakis; R A'Hern; G Lee; E Phillips; J Langdon
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

10.  Loss of heterozygosity is related to p53 mutations and smoking in lung cancer.

Authors:  S Zienolddiny; D Ryberg; M O Arab; V Skaug; A Haugen
Journal:  Br J Cancer       Date:  2001-01       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.